Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3339401rdf:typepubmed:Citationlld:pubmed
pubmed-article:3339401lifeskim:mentionsumls-concept:C0206441lld:lifeskim
pubmed-article:3339401lifeskim:mentionsumls-concept:C0019564lld:lifeskim
pubmed-article:3339401lifeskim:mentionsumls-concept:C0006462lld:lifeskim
pubmed-article:3339401lifeskim:mentionsumls-concept:C0599946lld:lifeskim
pubmed-article:3339401lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:3339401pubmed:issue1lld:pubmed
pubmed-article:3339401pubmed:dateCreated1988-3-8lld:pubmed
pubmed-article:3339401pubmed:abstractTextThe actions of 5-hydroxytryptamine (5-HT) and buspirone, an anxiolytic agent that displays high and selective affinity for 5-HT1A receptor sites, on synaptic activation of hippocampal CA1 pyramidal cells were studied in vitro. Whereas 5-HT application leads to a rapid hyperpolarization and decreased input resistance in pyramidal cells, buspirone has no measurable effects on membrane potential and input resistance. However, unlike 5-HT, buspirone application leads to a gradual and reversible reduction in excitatory postsynaptic potentials (EPSPs) elicited by stimulation of afferents in the stratum radiatum. Concurrent with this attenuation of the EPSP, buspirone decreases the excitability of afferent fibers in the stratum radiatum as evidenced by conduction slowing, increased refractory period, and decreased ability to generate repetitive impulses. 5-HT has no measurable effect on the afferent fibers. The attenuation of the EPSPs and the decrease in afferent fiber excitability appear to be independent of 5-HT receptors as 5-HT neither shares nor antagonizes the effects of buspirone. Thus, both 5-HT and buspirone can contribute to reduced spike activity in pyramidal cells, but they do so via different mechanisms: 5-HT hyperpolarizes pyramidal cells whereas buspirone attenuates their synaptic activation, possibly via action on the presynaptic fibers in the stratum radiatum.lld:pubmed
pubmed-article:3339401pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3339401pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3339401pubmed:languageenglld:pubmed
pubmed-article:3339401pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3339401pubmed:citationSubsetIMlld:pubmed
pubmed-article:3339401pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3339401pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3339401pubmed:statusMEDLINElld:pubmed
pubmed-article:3339401pubmed:monthJanlld:pubmed
pubmed-article:3339401pubmed:issn0270-6474lld:pubmed
pubmed-article:3339401pubmed:authorpubmed-author:PeroutkaS JSJlld:pubmed
pubmed-article:3339401pubmed:authorpubmed-author:KocsisJ DJDlld:pubmed
pubmed-article:3339401pubmed:authorpubmed-author:MaukM DMDlld:pubmed
pubmed-article:3339401pubmed:issnTypePrintlld:pubmed
pubmed-article:3339401pubmed:volume8lld:pubmed
pubmed-article:3339401pubmed:ownerNLMlld:pubmed
pubmed-article:3339401pubmed:authorsCompleteYlld:pubmed
pubmed-article:3339401pubmed:pagination1-11lld:pubmed
pubmed-article:3339401pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:meshHeadingpubmed-meshheading:3339401-...lld:pubmed
pubmed-article:3339401pubmed:year1988lld:pubmed
pubmed-article:3339401pubmed:articleTitleBuspirone attenuates synaptic activation of hippocampal pyramidal cells.lld:pubmed
pubmed-article:3339401pubmed:affiliationDepartment of Neurology, Stanford University School of Medicine, California 94305.lld:pubmed
pubmed-article:3339401pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3339401pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3339401pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:3339401pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3339401pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:3339401pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3339401lld:pubmed